US Heart Valve Treatments Market Fueled By New Transcatheter Valves

The combined US market value for products to treat heart valve disorders is expected to grow at a compound annual rate of 7.7%, increasing to $1.7 billion in the year 2019. Therapeutic management options for heart valve disorders include percutaneous balloon valvuloplasty (PBV), surgical valve repair, and surgical and percutaneous valve replacement. In addition, preventative and palliative medical/pharmacological therapy can be used in the management of patients with less severe heart valve disease. However, advances in percutaneous heart valve repair and replacement will likely lead to alterations in advanced valvular disease management strategies and will fuel market growth over the next few years. For example, US sales of transcatheter aortic valve replacement (TAVR) systems are set to almost triple to an estimated $662.5 million by 2019, according to a report from Medtech Insight (see Exhibit 1), and will mirror the strong growth seen in Europe, where these devices have been for sale for many years.

Exhibit 1